Controversial opioid Zohydro ER pulled from the market

As the Belgian pharma UCB recently inked a $1.9 billion deal to buy out Zogenix and its top drug for epilepsy, the company’s former controversial opioid has now been pulled from the market, according to a Federal Register filing by the FDA on Tuesday.